A lthough many studies have examined metabolic syndrome (MetS) and the Framingham Risk Score (FRS), few studies have been carried out in African populations. This limited information on MetS and FRS leaves us with an incomplete understanding of the prevalence and distribution of risk of cardiometabolic disease in sub-Saharan Africa (SSA). It also prevents us from critically evaluating how each of the varying definitions of MetS compares in African populations. A clearer understanding of MetS and FRS in African populations may provide the basis for better identifying the impact of these definitions and tools on disease risk and, furthermore, help to evaluate the usefulness of such tools for research and for informing public health care and prevention policy in SSA.
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In this study, we examined the prevalence and distribution of MetS and high (.20%) FRS and compare the World Health Organization (WHO), Adult Treatment Panel (ATP) III, International Diabetes Federation (IDF), and the newly proposed harmonized definitions of MetS in a rural Ugandan population (1) . A total of 8,087 participants, aged 13 years and older, were surveyed, of whom 7,423 (55% women) had complete data for analysis. Data were collected using standard procedures, and prediabetes was defined using HbA 1c $5.7% ($39 mmol/mol) (2) .
The prevalence of MetS varied by definition used, with the WHO, ATPIII, IDF, and harmonized definitions resulting in MetS prevalence of 4.1%, 9.9%, 8.9%, and 13.7%, respectively. The harmonized definition was the most sensitive, capturing all those identified using ATPIII and IDF and 85.4% of those identified using the WHO criteria. MetS increased with age (P value , 0.001), with a distinctive peak in the prevalence at ages 50-59 years for men for all definitions.
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